Fig. 3From: COVID-19 vaccination is associated with enhanced efficacy of anti-PD-(L)1 immunotherapy in advanced NSCLC patients: a real-world studySubgroup analysis according to the ICI treatment lines or physical conditions. PFS (A) and OS (B) between vaccinated and non-vaccinated groups in patients with first-line ICI treatment; PFS (C) and OS (D) between vaccinated and non-vaccinated groups in the ECOG 0–1 subgroupBack to article page